Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
| dc.contributor.author | CREDENCE Study Investigators | |
| dc.contributor.institution | University of Aberdeen.Medicine, Medical Sciences & Nutrition | en |
| dc.date.accessioned | 2024-03-12T10:14:00Z | |
| dc.date.available | 2024-03-12T10:14:00Z | |
| dc.date.issued | 2019-08-27 | |
| dc.description | Sources of Funding This study is sponsored by Janssen Research & Development, LLC, which funded the trial. The sponsor was involved in the study design, the writing of the report, and the decision to submit the article for publication. Canagliflozin has been developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation. Acknowledgments The authors thank all participants, investigators, and trial teams for their participation in the trial and the following people for their contributions to the statistical monitoring and analyses and the protocol development, safety monitoring, and operational implementation over the duration of the trial: Maria Ali, Jim Baldassarre, Dainius Balis, William Canovatchel, Jun Chen, Pei-Ling Chu, Trokon Cooke, Jag Craig, Jacki Danyluk, Mehul Desai, Lyndal Hones, Alan Jenkins, Mary Kavalam, Cha-Chi Lo, Xinchao Luo, Gary Meininger, Rich Oh, Rose Qiu, Nicole Schmitt, Danielle Siebenkaess, Roger Simpson, Anna Temu, Payal Thakkar, Michele Wells, and Renata Yong. The Steering Committee designed the study in conjunction with the sponsor. Dr Mahaffey wrote the first draft of the paper, had full access to the study design information, and had final responsibility for the decision to submit for publication. All authors provided input into subsequent drafts and approved the final version for submission. Editorial assistance for manuscript preparation was provided by Alaina Mitsch, PhD, and Kimberly Dittmar, PhD, of MedErgy, and was funded by Janssen Global Services, LLC. All authors reviewed and approved the manuscript. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 12 | |
| dc.format.extent | 446564 | |
| dc.identifier | 175571625 | |
| dc.identifier | 77be8bf6-a47c-44f4-9654-75e4b7834a0a | |
| dc.identifier | 000483552900013 | |
| dc.identifier | 85071325197 | |
| dc.identifier.citation | CREDENCE Study Investigators 2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial', Circulation, vol. 140, no. 9, pp. 739-750. https://doi.org/10.1161/CIRCULATIONAHA.119.042007 | en |
| dc.identifier.doi | 10.1161/CIRCULATIONAHA.119.042007 | |
| dc.identifier.iss | 9 | en |
| dc.identifier.issn | 0009-7322 | |
| dc.identifier.uri | https://hdl.handle.net/2164/22973 | |
| dc.identifier.vol | 140 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Circulation | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | canagliflozin | en |
| dc.subject | clinical trial | en |
| dc.subject | diabetes mellitus | en |
| dc.subject | primary prevention | en |
| dc.subject | renal insufficiency | en |
| dc.subject | chronic | en |
| dc.subject | secondary prevention | en |
| dc.subject | EMPAGLIFLOZIN | en |
| dc.subject | RATIONALE | en |
| dc.subject | EVENTS | en |
| dc.subject | DESIGN | en |
| dc.subject | RISK | en |
| dc.subject | R Medicine | en |
| dc.subject.lcc | R | en |
| dc.title | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- mahaffey_C_canagliflozincardiovascularrenal_VOR.pdf
- Size:
- 436.1 KB
- Format:
- Adobe Portable Document Format